Marker Therapeutics, Inc. (NASDAQ:MRKR) Sees Large Growth in Short Interest

Marker Therapeutics, Inc. (NASDAQ:MRKR) was the target of a large increase in short interest during the month of May. As of May 15th, there was short interest totaling 244,966 shares, an increase of 62.7% from the April 30th total of 150,562 shares. Approximately 1.6% of the shares of the stock are short sold. Based on an average daily volume of 64,788 shares, the short-interest ratio is presently 3.8 days.

Marker Therapeutics Price Performance

NASDAQ:MRKR opened at $1.47 on Friday. The firm has a market capitalization of $24.51 million, a PE ratio of -2.41 and a beta of 1.44. The business’s fifty day moving average price is $1.46 and its 200 day moving average price is $1.48. Marker Therapeutics has a 12 month low of $0.81 and a 12 month high of $4.07.

Marker Therapeutics (NASDAQ:MRKR) last posted its earnings results on Friday, May 15th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.02. The firm had revenue of $0.75 million for the quarter, compared to analyst estimates of $0.78 million. Marker Therapeutics had a negative return on equity of 73.29% and a negative net margin of 343.03%. As a group, equities analysts anticipate that Marker Therapeutics will post -1.17 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently commented on MRKR. HC Wainwright reiterated a “buy” rating on shares of Marker Therapeutics in a report on Wednesday, May 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Marker Therapeutics in a research note on Friday, March 27th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $10.00.

Hedge Funds Weigh In On Marker Therapeutics

Hedge funds have recently made changes to their positions in the company. Jane Street Group LLC acquired a new stake in shares of Marker Therapeutics during the second quarter worth about $33,000. Virtu Financial LLC purchased a new position in Marker Therapeutics in the third quarter valued at about $25,000. Two Sigma Investments LP purchased a new position in Marker Therapeutics in the third quarter valued at about $33,000. Boyer Financial Services Inc. purchased a new position in Marker Therapeutics in the fourth quarter valued at about $57,000. Finally, XTX Topco Ltd increased its stake in shares of Marker Therapeutics by 166.6% during the 4th quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock worth $86,000 after purchasing an additional 36,269 shares in the last quarter. Hedge funds and other institutional investors own 22.39% of the company’s stock.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.